BRIEF published on 05/08/2026 at 22:35, 14 days 12 hours ago Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
PRESS RELEASE published on 05/08/2026 at 22:30, 14 days 12 hours ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRIEF published on 02/11/2026 at 22:35, 3 months 11 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 3 months 11 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 6 months 12 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 6 months 12 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 7 months 29 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 7 months 29 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 1 year ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 1 year ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
Published on 05/23/2026 at 03:15, 8 hours 8 minutes ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 8 hours 23 minutes ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 8 hours 58 minutes ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 8 hours 58 minutes ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 10 hours 23 minutes ago LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Published on 05/22/2026 at 22:05, 13 hours 18 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 15 hours 32 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 16 hours 50 minutes ago Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 16 hours 53 minutes ago Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Published on 05/22/2026 at 18:05, 17 hours 18 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 22 hours 31 minutes ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 2 hours ago Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:45, 1 day 17 hours ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
